Volume 7, Issue 7, Pages 583-590 (July 2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study  Daniel G Healy, MD, Mario Falchi, PhD, Sean S O'Sullivan, MD, Vincenzo Bonifati, MD, Alexandra Durr, MD, Susan Bressman, MD, Alexis Brice, MD, Jan Aasly, MD, Cyrus P Zabetian, MD, Stefano Goldwurm, PhD, Joaquim J Ferreira, MD, Eduardo Tolosa, MD, Denise M Kay, PhD, Christine Klein, MD, David R Williams, MD, Connie Marras, MD, Anthony E Lang, MD, Zbigniew K Wszolek, MD, Jose Berciano, MD, Anthony HV Schapira, MD, Timothy Lynch, MD, Kailash P Bhatia, MD, Thomas Gasser, MD, Andrew J Lees, MD, Nicholas W Wood, MD  The Lancet Neurology  Volume 7, Issue 7, Pages 583-590 (July 2008) DOI: 10.1016/S1474-4422(08)70117-0 Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 1 Age of PD onset plotted against the cumulative percentage of patients in the PARK2, LRRK2, or QSBB series QSBB=Queen Square brain bank. The Lancet Neurology 2008 7, 583-590DOI: (10.1016/S1474-4422(08)70117-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 2 Point prevalence of neuropsychiatric symptoms in patients with mutations in LRRK2 after various durations of the symptoms of PD The Lancet Neurology 2008 7, 583-590DOI: (10.1016/S1474-4422(08)70117-0) Copyright © 2008 Elsevier Ltd Terms and Conditions

Figure 3 Age-specific risk of PD Risk is estimated with the Kaplan-Meier method for the whole sample and with the maximum-likelihood estimation (ML) for all patients with mutations in LRRK2 combined. The Lancet Neurology 2008 7, 583-590DOI: (10.1016/S1474-4422(08)70117-0) Copyright © 2008 Elsevier Ltd Terms and Conditions